The University of Southampton
University of Southampton Institutional Repository

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Background: Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.

Methods: This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for Centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0.71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479.

Findings: In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1-6) preoperative cycles and 115 (63%) patients received a median six (1-8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7.3% (from 28.1% [95-66% CI 21.3-35.51 to 35.4% [28.1-42.7]; HR 0 . 79 [0.62-1.02]; p=0.058) in randomised patients; 8 . 1% (from 28.1% [21.2-36.6] to 36.2% [28.7-43.8]; HR 0 . 77 [0-60-1 . 001; p=0 . 041) in eligible patients; and 9.2% (from 33.2% [25.3-41.2] to 42.4% [34.0-50.5]; HR 0.73 [0.55-0.97]; p=0.025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0.04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group.

Interpretation: Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected. patients. Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis
surgery, trial, patient, cancer, cycle, fluorouracil, time, care, combination, leucovorin, plus irinotecan, folinic acid, liver, colon-cancer, relapse, colorectal-cancer, surgical resection, hepatic arterial infusion, chemotherapy, protocol, progression-free survival, oxaliplatin, 5-fluorouracil, death, risk, colorectal cancer, adjuvant chemotherapy, survival
0140-6736
1007-1016
Nordlinger, Bernard
fb274f17-eeb2-4eea-8dd9-2e8c5d1d24ad
Sorbye, Halfdan
c1f4282f-9114-4763-863b-062f2bcd0de9
Glimelius, Bengt
d173ea78-352c-40b9-b8e3-38c2f9f6a8a6
Poston, Graeme J.
b4f0b717-5c25-4c81-89cb-64bc2840106e
Schlag, Peter M.
9a09978f-0b1a-4ae7-bffb-43f888dab093
Rougier, Philippe
c49687fa-84ac-4252-9a6d-7ce9673b4d06
Bechstein, Wolf O.
a437504c-c25e-48b1-a298-f078cea88adc
Primrose, John N.
d85f3b28-24c6-475f-955b-ec457a3f9185
Walpole, Euan T.
e2837322-a99f-47b3-a99a-96fac90b00da
Finch-Jones, Meg
5e1f7fc9-5be8-4d7a-9ccc-7b1b6a1f7f80
Jaeck, Daniel
2f51b0b5-e276-437d-8b3e-e2e5de26bb1e
Mirza, Darius
0a0e4aff-30ff-4b0f-8d25-f675db71afe5
Parks, Rowan W.
fa68779f-9dc1-4b66-9708-58fcc3afca3f
Collette, Laurence
d624d8db-44f5-45dc-8e13-0138f0a12ad0
Praet, Michel
588747c2-4442-4ca2-852f-6f4c23a82d0c
Bethe, Ullrich
6ad57b39-a53f-4ac9-9582-f2d5d545c82f
Van Cutsem, Eric
071a0b63-a2e6-4424-b31d-a86c2bc09cf4
Scheithauer, Werner
ef5362dd-a297-4a6e-b555-6375f841cdd0
Gruenberger, Thomas
3e909c56-b9e9-4a37-a28e-305c41205525
Nordlinger, Bernard
fb274f17-eeb2-4eea-8dd9-2e8c5d1d24ad
Sorbye, Halfdan
c1f4282f-9114-4763-863b-062f2bcd0de9
Glimelius, Bengt
d173ea78-352c-40b9-b8e3-38c2f9f6a8a6
Poston, Graeme J.
b4f0b717-5c25-4c81-89cb-64bc2840106e
Schlag, Peter M.
9a09978f-0b1a-4ae7-bffb-43f888dab093
Rougier, Philippe
c49687fa-84ac-4252-9a6d-7ce9673b4d06
Bechstein, Wolf O.
a437504c-c25e-48b1-a298-f078cea88adc
Primrose, John N.
d85f3b28-24c6-475f-955b-ec457a3f9185
Walpole, Euan T.
e2837322-a99f-47b3-a99a-96fac90b00da
Finch-Jones, Meg
5e1f7fc9-5be8-4d7a-9ccc-7b1b6a1f7f80
Jaeck, Daniel
2f51b0b5-e276-437d-8b3e-e2e5de26bb1e
Mirza, Darius
0a0e4aff-30ff-4b0f-8d25-f675db71afe5
Parks, Rowan W.
fa68779f-9dc1-4b66-9708-58fcc3afca3f
Collette, Laurence
d624d8db-44f5-45dc-8e13-0138f0a12ad0
Praet, Michel
588747c2-4442-4ca2-852f-6f4c23a82d0c
Bethe, Ullrich
6ad57b39-a53f-4ac9-9582-f2d5d545c82f
Van Cutsem, Eric
071a0b63-a2e6-4424-b31d-a86c2bc09cf4
Scheithauer, Werner
ef5362dd-a297-4a6e-b555-6375f841cdd0
Gruenberger, Thomas
3e909c56-b9e9-4a37-a28e-305c41205525

Nordlinger, Bernard, Sorbye, Halfdan, Glimelius, Bengt, Poston, Graeme J., Schlag, Peter M., Rougier, Philippe, Bechstein, Wolf O., Primrose, John N., Walpole, Euan T., Finch-Jones, Meg, Jaeck, Daniel, Mirza, Darius, Parks, Rowan W., Collette, Laurence, Praet, Michel, Bethe, Ullrich, Van Cutsem, Eric, Scheithauer, Werner and Gruenberger, Thomas (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet, 371 (9617), 1007-1016. (doi:10.1016/S0140-6736(08)60455-9).

Record type: Article

Abstract

Background: Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.

Methods: This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for Centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0.71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479.

Findings: In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1-6) preoperative cycles and 115 (63%) patients received a median six (1-8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7.3% (from 28.1% [95-66% CI 21.3-35.51 to 35.4% [28.1-42.7]; HR 0 . 79 [0.62-1.02]; p=0.058) in randomised patients; 8 . 1% (from 28.1% [21.2-36.6] to 36.2% [28.7-43.8]; HR 0 . 77 [0-60-1 . 001; p=0 . 041) in eligible patients; and 9.2% (from 33.2% [25.3-41.2] to 42.4% [34.0-50.5]; HR 0.73 [0.55-0.97]; p=0.025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0.04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group.

Interpretation: Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected. patients. Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis

This record has no associated files available for download.

More information

Published date: 2008
Keywords: surgery, trial, patient, cancer, cycle, fluorouracil, time, care, combination, leucovorin, plus irinotecan, folinic acid, liver, colon-cancer, relapse, colorectal-cancer, surgical resection, hepatic arterial infusion, chemotherapy, protocol, progression-free survival, oxaliplatin, 5-fluorouracil, death, risk, colorectal cancer, adjuvant chemotherapy, survival
Organisations: Cancer Sciences, Clinical Trials Unit

Identifiers

Local EPrints ID: 62869
URI: http://eprints.soton.ac.uk/id/eprint/62869
ISSN: 0140-6736
PURE UUID: a9251719-3ba1-49b1-804a-06b06d7b4727
ORCID for John N. Primrose: ORCID iD orcid.org/0000-0002-2069-7605

Catalogue record

Date deposited: 05 Sep 2008
Last modified: 16 Mar 2024 02:47

Export record

Altmetrics

Contributors

Author: Bernard Nordlinger
Author: Halfdan Sorbye
Author: Bengt Glimelius
Author: Graeme J. Poston
Author: Peter M. Schlag
Author: Philippe Rougier
Author: Wolf O. Bechstein
Author: Euan T. Walpole
Author: Meg Finch-Jones
Author: Daniel Jaeck
Author: Darius Mirza
Author: Rowan W. Parks
Author: Laurence Collette
Author: Michel Praet
Author: Ullrich Bethe
Author: Eric Van Cutsem
Author: Werner Scheithauer
Author: Thomas Gruenberger

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×